Drugs / AZD8330
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00454090 | Mar 2007 → Oct 2010 | cancer | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD8330 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00454090 ↗ |
| Known as | ARRY-424704 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3182621 ↗ |
| Known as | ARRY-704 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3182621 ↗ |
| Action | Inhibit | “This is the first clinical study of the MEK1/2 inhibitor AZD8330 (ARRY-424704).” PMID 23433846 ↗ Feb 20132“Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL3182621 ↗ “Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL3182621 ↗ |
| Modality | Small molecule | — CHEMBL3182621 ↗ |
| Route | Oral | “Patients with refractory cancer or cancer with no standard therapy received either once-daily (OD) or twice-daily (BID) oral AZD8330” PMID 23433846 ↗ Feb 2013 |
| Target | MAP2K1 | “Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL3182621 ↗ |
| Target | MAP2K2 | “Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL3182621 ↗ |